Related references
Note: Only part of the references are listed.Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model
Mark T. Bilodeau et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
The PI3K/Akt pathway: Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors
Craig W. Lindsley et al.
CURRENT CANCER DRUG TARGETS (2008)
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sreenath V. Sharma et al.
GENES & DEVELOPMENT (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H. Saal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN
Xinjiang Wang et al.
CELL (2007)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
QB She et al.
CANCER CELL (2005)
Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasis
O Tschopp et al.
DEVELOPMENT (2005)
Functional and therapeutic significance of Akt deregulation in malignant melanoma
GP Robertson
CANCER AND METASTASIS REVIEWS (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors
SF Barnett et al.
BIOCHEMICAL JOURNAL (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice
D Finkle et al.
CLINICAL CANCER RESEARCH (2004)
Relevance of breast cancer cell lines as models for breast tumours: an update
M Lacroix et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Promoter methylation of the PTEN gene is a common molecular change in breast cancer
JM García et al.
GENES CHROMOSOMES & CANCER (2004)
The PIK3CA gene is mutated with high frequency in human breast cancers
KE Bachman et al.
CANCER BIOLOGY & THERAPY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
T Holbro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model
PK Majumder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice
M Butler et al.
DIABETES (2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ)
H Cho et al.
SCIENCE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
